Business
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a c
About this update from Briacell Therapeutics Corp
[{"type":"image","alt":"BriaCell Therapeutics Corp.","displaySize":"","headline":null,"caption":"BriaCell Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VF.3uZP0Y9S.3O0ulWOxbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7","width":300,"height":263}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"No Bria-IMT™ related discontinuations reported to date","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Bria-IMT regimen continues under Fast Track Designation from US FDA","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":323,"olType":false},{"type":"text","content":"PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment.","length":494,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"5","style":"width:99.9867%;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:bottom;","val":[{"type":"text","content":"Table 1: Ongoing Long-Term Survivors","length":36,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:27%;width:27.0186%;min-width:27%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:bottom;","val":[{"type":"text","content":"Patient/Subtype","length":15,"tagName":"p","attribs":{}}]},{"style":"max-width:17%;width:16.9755%;min-width:17%;border-top:solid black 1pt;border-right:solid bla...